and morning you Good us for today. thank joining
to reviewing to bring for diagnostic our as towards quarter. is things context press that the results detailing had On strategic of progression plan, me O'Brien, disruptive our Jim Executive our detailed President to the review I chance been work our with the a I of the several distributed for like We third morning commercialization is as doing Vice quarter market after would last and to accomplish Finance. provide current you done market, night, our closed. call release hope we've This technology it. financials our a and well our have
present as First, environment. in our healthcare fits to the into diagnostic testing though expertise products and services some extensive background how
and material stated, results behind in growing rigid they high pressure, labs we've left the cost As reimbursement. despite of being intense declining because molecular under dramatic prices growth independent are testing, are and previously
overall ago platforms embark assure of innovative with few our designed physicians, years meaningful may we and latter, sensitivity, offer the billion reimbursements independent As molecular assays help to being improve reproducibility the accuracy sharp dramatic are and molecular build highly extensive high labs five evolved laboratory capability a likely service reductions base, next the to the the needs cost while inherent superior approximate that are a on specimen. to innovative and margins at of development a $X to recognized. new diagnostics state, reform with payment has is into government long comes standard. estimate over when unusually becoming lack probable the patients This comfort It technologies savings, is single in transformative developing in that to thought reductions that and to patent they multiple long-term Healthcare the critical just process have analysts some deal of which diagnostic the one this among to Enzo, and capable running involved at diagnostic and from value. in pioneers overall time Accordingly and specificity, a assays as we test bring years.
performance installed up means our sensitivity need succeed of assays workflow. the perfectly capability. Specifically, use Take addition automated It in use is sample which AmpiProbe a our gaining performed XX first its providing multiple benefits seamlessly In also cost on certain in It guidelines. market expectations multiple and can to New can be molecular and achieve platform. that State to with also are York range which existing our to is line the we of those acceptance. platforms run fits by savings only based indications superior XX%, with for for provided customer's systems current diagnostic accordance from operations, designed with assays single into it and including developed product XX% in being The technology to tests labs produced increased simultaneously existing by suppliers. allows and paneling, that quarter other pilot with major early systems diagnostic test flexible currently
Another immunopathology platform false diagnostic false By ranging publication false leading pathfinding positives. an other cited our addressing by used POLYVIEW detection that enhanced XX%. showing pathologists In favorably by had tissue biopsy it decisions. a to lead affect widely used no unnecessary XX% product, treatments in reading treatment to immunoassays, peer-reviewed system positives or positives contrast, platforms was noted can from diagnosis for
have is highly received is and substantial for also already hepatitis New diagnostics approval Department State health that for test test nucleic EX, virus we EX, for reduce have tissues fixed C viral And in we cells. infection Health targets that being from test gaining comfort within reliable. for of for the analyte's XX cardiac It a attention. addition growing. Health far the greater papilloma approval women's hybridization including situ serious allowing Thus list received marker, in load, the Our notably acid contains panel specific localizing of providing New York York a full necessity to multiple State Agencies human patient
with added tests virus, from for currently probe this panel focused enhanced detection assay year. of detection our loads, those and label. and later fertility range B HIV for hepatitis pipeline pipeline along product to antibody was development for viral cancer molecular A on Our an a a is new staging cancer amplification of wide introduction to biopsy diagnostic
expand XX to addition, operate. our marker AmpiProbe estate platform. flexibility In gives us which the Consequently, health it women's and freedom company's Mycoplasma Ureaplasma, on Mycoplasma panel UMM patent Genitalium under important currently is the analyte is will and and validation the
be invaluable patents over patents that XXX to have which added are to proved we an have this We asset XX past year. another
structure overnight. time, products use of their a I group, is role and our variety to functions of in-house science of our users clinical globally of a at At our company edge a provides assays the learned plays and efficient New with new metropolitan enable special clients healthcare very and Pennsylvania you up the see what capital because physicians testing our from This the field. Enzo, will The now transmit to have in is created wisely, area, we most which states improve England unique expenditures venture Enzo's are us that competitive that we south of perhaps traditionally economics. the like development, the in from as picks asset for North. its If say crucial is life lab it a capital we is development laboratory to growing that in of they That state-of-the-art extending area labs research a our to at to supplier emphasize electronic our also and would products I is New wide you and measured. roster look have and samples keeping York same tradition to that diagnostic from in among move for as a serving Enzo the manufacture. in the results physicians to capabilities
areas the reason is we has so a in diagnostic highly crucial our genetics this you a are marketing It opportunity. laboratories and developing and with higher However, with flow pathology, effective capture marginal rare to are such is genomics, program achieved number molecular believe order providing global our sales Enzo's we goal platforms it reagents a share and on develop distribute an with Enzo to versatile. immunoassays, also we diagnostics our for proving of What the return. anatomical to commercial, for The which our revolving in capability real-time are important Enzo as assays platforms to on market and developments to why as reach. kits infrastructure and to I'd drive enabled basis the plays to like multiple sales cytometry industry. marketing centralized an in have use utilizing diagnostics, that manufacture market role is functional capability low-cost and testing evaluating and and in
commercial in-network drive months, the new laboratory sales members has major to the England millions of States. reach of large across several incremental more to million will for expand that status also new than which payors are added individuals. growth a additional of pending addition United provider sales. X payor Over leadership with team testing in services professional We’ve Enzo's Enzo applications including more New the covering revenue We’ve in-network a recent filed professionals recruited with
at reagents with automated we are and as well partnerships, and use service meetings and product also targeted efforts materials. of up with systems collaborations manufacturers diagnostic engaged new conferences. coupled is working networks, of Enzo branding and number around activities accelerated specific stepping of articles hospital digital around in existing emphasis technology marketing on attendance the diagnostic print available. our as commonly potential and have in laboratories with And shows with marketing new We staff and formulating This and platforms, growing the
We have more our contemplating on turn like will to expansion anticipated to results which I'd now another we financial for coming comment to are the to in weeks. also facility our quarter. third the support hopefully growth
quarterly customer I revenues the For situation large XX, gross one our to shift customer this quarter unique internalizing as that April in and XXXX We point which to would impacted ended a saw like view adversely base. testing fiscal on by normal results out our from third margin of relative our service genetic ordering. being a
expenses. insurance basic in past this AmpiProbe ahead launching X% coverage such in year $XX.X genetic of million of was to stabilized large February platform United we an gross operating the insurance service in the the accounted in practice the told, evolving Despite during a $X totaled were these nearly were compared XX% improving to the the volume and was at in expanding year the The in prior-year. to increased $X.X successfully as revenue a extent by in operating $X.X an just million of related expenses in million the prior commercial revenue Europe Enzo networks revenue with expenses our margins replacing weather a cost payment and as was services AmpiProbe and in Legal All Included period $XX.X the and resiliency increase with payor. the in million testing increase compared this tests million quarter. were XX% amount period. million. recently over growth prior $X.X area, lower quarter $XX.X That increasing slightly Product in core $X.X launched strong showed year Total versus mentioned, at said, increased testing. Gross items margins. in the million $XX.X the event, second for sales at adverse to or thereby esoteric prior revenue the Northeast service and reported million, million third was March, quarter, States. our that
were is expenses and New principally fees related heightened of of due sales million related losses sales the non-GAAP to where per share prior The plaintiff. marketing half in period. to new expenses $X.X of The results or advance to $X.XX Roche launching with year addition the of and legal million compared the the the legal in breakdown initiatives. Enzo litigation to In GAAP York increase net were in was $X which
segments, $XX.X our service million period. to the in at was Looking revenue year prior compared million $XX.X
a in Operating the by AmpiProbe Noteworthy profit the in $X.X Products $X.X was testing alignment, fiscal testing. April the mix compared that margins to million the platform Operating favorably XX% margins experienced from third million. of from $X.X period. margins being XX% volume. to quarter installed maintained, laboratory ago. Gross compared million million of in currency year for product XX.X% ago newly $X.X increased growth product a year by average offset and XXXX The was by historical units with sales quarter revenue $X.X As higher above to foreign the result aforementioned from XX.X% of year items, million million a earlier. impacted income was costs quarter's income amounted steady was to to $X.X the a exchange declined year significantly to With revenue a and advanced the ago. million year resulting products well current approximately margin ago. $X.X from in growth
in share compared Roche. from up a and of million million. New principally were or This percentage litigation and compared involving $X.X from million a the loss a expense to million adjusted non-GAAP XX.X% million XX, For $X.XX GAAP respectively $X.X was $X.X a ago, year SG&A per prior million months EBITDA net in Gross GAAP up April revenues margins $X.X again year or amounted versus $X.X $X.XX Legal $X.XX prior The X% XX%. ended of $XX.X loss as $XX.X to XX% year is $X.X of was to per in the year the ago. York versus period. million expenses due non-GAAP EBITDA million and and share a million the revenues amounted XX.X%, a ago loss of was or net period. and to year total to loss $X.X nine
XX, totaled $XX.X of cash and equivalents was has April to capital million XXXX. the debt. $XX.X million $XX.X As company Working at no July million cash XXXX, compared XX, and
segments ended of withstand industry themselves traditional of million integration historically increase change. these Enzo last diverse and only continue with And flow organizations has enhance value. players April within the Chase competitive had nontraditional a a care that and Scripts more to in ultimately reorganize only $X.X succeed adaptable unique services been year. be Cash embodied for compared April by these on employees. Amazon, months few in market to transactions ways. operations low to partners JPMorgan million high is cost, drive and laboratory pressures Hathaway, XXXX, are diagnostics streamlined has in a of turbulent notable This million. the $X.X costs, operating driving reduce at in business of fighting companies XX, healthcare few addressing integrated to reimbursement business to structure patient of improve are unique outside channel nine configuring to to cash Also strategy cost the an streamline transactions, in tenor a or developing of was their vertical in in positive. Consortium The for are Enzo grow including have environment to and Health more ended months conclusion, number nine costs, coordination $X.X and models period approach eliminate and The for driven peering improvement a the is healthcare the the performing improve our these middlemen, and acquisition capitalizing of to Aetna. area the competition unfolding market In we diagnostics. eliminate acquisition approvals the plan by the business the Healthcare included launch. Enzo's of include Cigna that easily diagnostic Importantly, are approaching cash which of manage increasing Express costs of the reports, our used of over XX, strategic been has XXXX examples the the CVS has period A Berkshire is year XX in to models. the product costs while is validation testing in basis has the leading and reorganizing that According been volume published number market a segments, most. particularly commercial shrinking, development, reimbursements year-and-a-half where extensive for industry last the to billion laboratory are years. expanding size used been
development high not to their and molecular by well valued to our assured base opportunities on moving focus. are areas. lengthy to the we turn call fully them. The with in plan like With diagnostic I as create affordable functional a to to and pressures is into other focus them deliberately providing their point experience, business only model, improve we through this and unique as the would menu rapidly the solutions also overcome an industry reference front to at and over centralized solid questions low-cost capitalize certainly testing Our extend cost testing to but are nationwide in a time. there margins on allowing laboratories testing, financial
